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RESUMO – Introdução: Os agentes biológicos assumiram uma relevância crescente no âmbito da Dermatologia. Contudo, 
os eventos adversos (EA) associados a estes tratamentos e as razões para a sua suspensão não estão totalmente esclareci-
dos. O Objectivo deste estudo é analisar os motivos que conduziram à suspensão de terapêuticas biológicas e caracterizar o 
perfil de EA na população de doentes sob esta terapêutica. Material e Métodos: Estudo observacional descritivo dos doentes 
acima de 18 anos sob terapêutica biológica no Serviço de Dermatologia do Hospital de Santarém EPE, entre Janeiro/2007 
e Dezembro/2017. Foram avaliadas as causas de suspensão terapêutica, definida como a omissão de pelo menos 2 ad-
ministrações consecutivas do fármaco, independentemente do motivo implicado e da existência, ou não, de recomendação 
médica para tal. Resultados: Foram avaliados 262 ciclos de tratamento, correspondentes a 138 doentes. Psoríase foi o 
diagnóstico predominante (93,5% dos doentes). Foram avaliados ciclos de tratamento com 8 biológicos, tendo o etanercept 
(46,6%), o adalimumab (31,3%) e o ustecinumab (12,6%) sido os mais representados. No período em estudo registaram-se 
167 suspensões, invocando-se 170 justificações. Os fundamentos mais frequentes para a suspensão dos biológicos foram: 
falência primária ou secundária (35,3%), EA (31,2%), factores relacionados com o doente/má adesão à terapêutica (17,1%), 
intervenção cirúrgica (7,1%) e excelente resposta clínica/ausência de lesões (6,5%). Nas suspensões terapêuticas motivadas 
por EA (n=53), as infecções foram a causa mais frequente (35,8%, n=19), seguidas de neoplasias (15,1%, n=8), alterações 
hematológicas (13,2%, n=7), sintomatologia neurológica (9,4%, n=5) e reacções no local da injecção (5,7%, n=3). Con-
clusão: A principal causa de suspensão de biológicos foi a falência terapêutica, logo seguida dos EA. Dois padrões distintos 
de suspensão dos biológicos foram aparentes: a descontinuação definitiva, geralmente decretada pelo médico por falência 
terapêutica primária ou secundária, e a suspensão temporária, frequentemente sem indicação médica formal, por EA, mais 
tarde retomando o mesmo agente biológico. Determinámos uma incidência superior de ciclos terapêuticos suspensos por EA 
do que o reportado na literatura. As suspensões temporárias por EA, frequentemente não valorizadas pelo dermatologista, 
são provavelmente sub-reconhecidas e contribuem para um padrão deficitário de utilização dos biológicos, com prejuízo dos 
resultados clínicos obtidos.  
PALAVRAS-CHAVE – Suspensão do Tratamento; Terapia Biológica/efeitos adversos.
Why do we Discontinue Biologic Agents? 
A Retrospective Study of 11 Years   
ABSTRACT – Introduction: Biologic agents acquired a growing relevance in dermatology, however, adverse events (AE) and 
reasons to discontinue therapy are not completely known. The objective of this study is to analyse the reasons behind the discon-
tinuation of biologics and characterize the AE in this population of patients. Material and Methods: Descriptive observational 
study, including patients over 18-years-old under treatment with biologic agents in the Dermatology Department of Hospital de 
Santarém, Portugal, between January/2007 and December/2017. We analysed reasons for therapeutic discontinuation, defined 
as the omission of at least 2 consecutive administrations, whatever the reason implicated and whether or not proposed by the 
dermatologist. Results: A total of 262 cycles of treatment were performed, in 138 patients (59.4% male, 40.6% female). Psoriasis 
was the most prevalent diagnosis (93.5% of the patients). Cycles of treatment with 8 biologic agents were analysed: etanercept 
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INTRODUCTION
Biologic agents have acquired a growing relevance in 
dermatology. It is common to emphasize the increase in effi-
cacy they provide to control multiple dermatoses. However, 
long-term safety profiles and associated adverse events (AE) 
are not completely known.1 Clinical trials usually include hi-
ghly selected populations, focus mainly on therapeutic effi-
cacy, have limited follow-up periods and do not allow us to 
know entirely the safety profile of these drugs in real life. 
Although there are several recent publications on the real-
-world evidence showing that patients often have to discon-
tinue treatment and/or switch biologic agents over time due 
to loss of effectiveness or AE,2-6 literature has focused mostly 
on severe AE leading to definitive therapeutic discontinua-
tion and therapeutic switches, or “drug survival”, as a useful 
measure for evaluating the long-term treatment success of a 
biologic treatment in the real-world setting.2,7,8
All the causes that lead to definitive, or especially to tran-
sient therapeutic discontinuation, that we want to address in 
particular, are not so well-known and there is a scarcity of 
published data in the Portuguese population. Therefore, the 
objective of our study was to characterize discontinuation of 
biologic agents in a national dermatology department and 
analyze the underlying reasons, as well as the AE, evaluating 
both discontinuations decided by the physician and those wi-
thout medical advice. Evaluation of drug survival was not, 
however, our primary outcome.
METHODS
A descriptive observational study was performed, inclu-
ding patients over 18-years-old under biologic treatment in 
the Dermatology Department of Hospital de Santarém, Por-
tugal, between January/2007 and December/2017. Epide-
miological and clinical data were reviewed from data on file 
and missing information was gathered via direct contact with 
the patient. The concept of “therapeutic discontinuation” was 
defined as the omission of at least 2 consecutive administra-
tions of the biologic agent, in line with the concept used by 
Belinchón et al,9 whatever the reason, whether or not orde-
red by a dermatologist and whether or not the patient later 
resumed the same biologic, switched to another one or was 
started on another therapeutic modality. The length of time 
the patient was continuously taking the biologic agent, not 
skipping more than one administration, was defined as a 
“cycle of treatment”. No distinction could be performed be-
tween naive and bio-experienced patients. The AE included 
in the analysis were occurrences registered in the clinical re-
cords as causes of discontinuation, with a presumed rela-
tionship with the biologic agent, but the degree of severity 
could not be evaluated. 
For the data analysis, binary and categorical variables 
were summarized by counts and percentages, and conti-
nuous variables by means. For each one of the most repre-
sented biologics, analysis was performed comparing number 
of discontinuations and percentage due to AE, period until 
the first discontinuation due to AE, differences in the number/
percentage of discontinuations caused by each major AE and 
length of treatment until discontinuation for each of them. 
Comparison of means was performed using the independent 
samples t-test and ANOVA. Statistical analysis was perfor-
med using the IBM SPSS Statistics 23.0 (SPSS, Chicago, IL, 
USA). The level of significance was considered for p<0.05.
RESULTS
During the period of 11 years under analysis, biologic 
agents were prescribed to 138 patients, 82 males (59.4%) 
and 56 females (40.6%), both naive and biologic-experienced 
patients. Detailed epidemiological and clinical data are dis-
played on Table 1. Psoriasis was the predominant diagnosis 
(129/138), followed by hidradenitis suppurativa (4/138), pyo-
derma gangrenosum (2/138), dissecting cellulitis of the scalp 
(1/138), SAPHO (synovitis, acne, pustulosis, hyperostosis and 
osteitis) syndrome (1/138) and PASH (pyoderma gangreno-
sum, acne and hidradenitis suppurativa) syndrome (1/138). 
A total of 262 cycles of treatment were performed and 8 
different biologic agents were used during this period, with 
etanercept, adalimumab and ustekinumab representing, 
respectively, 46.6%, 31.3% and 12.6% of the total cycles of 
therapy (Fig. 1). On average, patients were treated with 1.4 
biologic agents and performed 1.9 cycles of treatment. One 
hundred patients (72.5%) were treated with one single biolo-
gic drug during the period under analysis but 27.5% of the 
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(46.6%), adalimumab (31.3%) and ustekinumab (12.6%) were the most represented. During the study period, 167 suspensions 
were registered, for which 170 justifications were indicated. The most prevalent causes were: primary or secondary therapeutic 
failure (35,3%), AE (31.2%), factors related to the patient/noncompliance (17.1%), surgical intervention (7.1%) and excellent cli-
nical response/absence of lesions (6.5%). Among therapeutic discontinuations motivated by AE (n=53), infections were the most 
frequent cause (35.8%, n=19), followed by malignancies (15.1%, n=8), hematological abnormalities (13.2%, n=7), neurologi-
cal symptoms (9.4%, n=5) and local reactions at the injection site (5.7%, n=3). Discussion: The main cause for discontinuation 
of biologics was therapeutic failure, immediately followed by AE. Two different patterns of discontinuation were apparent: defi-
nitive suspension, commonly decided by the physician due to primary or secondary therapeutic failure, and temporary disconti-
nuation, frequently without formal medical indication, due to AE, later resuming the same drug. We found a higher percentage 
of therapeutic cycles discontinued due to AE than reported in the literature. Temporary suspensions of the biologics due to AE, 
often not sufficiently valued by the dermatologist, are probably under-recognized and contribute to a suboptimal pattern of use 
of biologics and worse clinical outcomes
KEYWORDS – Biological Therapy /adverse effects; Withholding Treatment.
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patients were prescribed more than 1 agent (range 2-6 drugs; 
2 drugs: 18.9%; 3 drugs: 6.5%; 4 drugs: 0.7%; 5 drugs: 0.7%; 
6 drugs: 0.7%). At the end of the study period neither secuki-
numab nor ixekizumab had treatment periods that were long 
enough to measure adherence at 12 and 24 months.
During these 11 years, 167 discontinuations of treatment 
with biologic agents occurred, for which 170 justifications 
were indicated (in 3 cases there were 2 reasons invocated to 
discontinue treatment). Infliximab and etanercept presented 
the highest percentages of patients missing at least 2 conse-
cutive administrations, both during the first 12 and 24 mon-
ths of therapy, and ustekinumab showed the longest average 
time of treatment until the first discontinuation for any reason 
and, specifically, due to AE (Table 2). Ixekizumab had no dis-
continuations during the period in analysis.
Justifications to discontinue the biologics were primary 
or secondary therapeutic failure (n=60, 35.3%), AE (n=53, 
31.2%), factors related to the patient/noncompliance to 
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Table 1 - Epidemiological and clinical data of the patients treated with each biologic, namely number of 
patients that used each drug, their sex distribution, average age at the onset of treatment, time since diagnosis, 
use of concomitant systemic therapies and comorbidities (diabetes mellitus, hypertension and dyslipidemia). 
Patients
Treated 
(n)
Sex 
distribution
M/F
Age at onset 
of treatment
Time since 
diagnosis
(years)
Concomitant 
systemic 
therapy (%)
Diabetes 
Mellitus
(%)
Arterial 
hypertension
(%)
Dyslipidemia
(%)
Etanercept 86 52/34 50.0 16.3 29.1 17.4 38.4 37.2
Adalimumab 58 38/20 49.2 17.5 37.9 22.4 48.3 44.8
Ustekinumab 30 17/13 48.2 20.0 23.3 16.7 30.0 23.3
Infliximab 12 4/8 46.0 17.5 41.7 0.0 33.3 8.3
Secukinumab 3 1 /2 40.0 26.0 33.3 0.0 0.0 0.0
Ixekizumab 1 1/0 57.0 32.0 100.0 0.0 0.0 0.0
Efalizumab 3 2/1 38.7 14.0 0.0 33.3 66.7 66.7
Golimumab 1 0/1 52.0 13.0 100.0 0.0 100.0 100.0
Total 194* 115/79*
*38 patients were treated with more than one biologic agent (range 2-6)
Figure 1 - Distribution of the cycles of treatment by biologic agent (n=262). 
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the treatment (n=29, 17.1%), surgical intervention (n=12, 
7.1%), excellent clinical response/absence of lesions (n=11, 
6.5%), pregnancy (n=3, 1.8%) and other causes (n=2, 1.2%) 
(Table 3). 
For the most represented agents, therapeutic failure mo-
tivated discontinuation of 29.4% of cycles for infliximab, 
25.6% for adalimumab, 22.1% for etanercept and 12.1% 
for ustecinumab. In the case of suspension due to therapeu-
tic failure (n=60), it was advised by the physician in 96.7% 
(n=58) of the cases, with switch to another biologic agent 
in 93.3% (n=56).
AE was the cause of therapeutic discontinuation of 20.2% 
(n=53) of the total 262 cycles of treatment, 26.2% for eta-
nercept, 17.6% for infliximab, 15.2% for ustekinumab and 
14.6% for adalimumab. Among AE, infections, mostly respi-
ratory infections, were the most frequent cause of therapeutic 
discontinuation (n=19, 35.8%), followed by malignancies 
(n=8, 15.1%), hematological abnormalities (n=7, 13.2%), 
neurological symptoms (n=5, 9.4%) and local reactions at 
the injection site (n=3, 5.7%). There were 8 different cases 
of malignancy diagnosed, with no discernible predominant 
pattern: cutaneous melanoma, prostatic adenocarcinoma, 
endocervical adenocarcinoma, glioma, pelvic sarcoma, 
breast adenocarcinoma, penile squamous cell carcinoma 
and ampulla of Vater carcinoma. Hematological abnormali-
ties were mainly cytopenias, particularly thrombocytopenia. 
On average, for patients who discontinued due to AE, treat-
ment was performed for 24.0 months until the first suspen-
sion. Regarding discontinuations due to AE (n=53), they 
were unilaterally decided by the patient in 35 cases (66.0%) 
and advised by the physician in 18 (34.0%). After disconti-
nuation, the same medication was reintroduced in 30 cases 
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Table 2 - Number of cycles of treatment for each biologic agent, respective number of discontinuations, time 
to the first discontinuation in all cases and when due to an AE and percentage of continuous therapeutic 
adherence/persistence at 12 and 24 months. 
Treatment cycles
(n)
Number of
discontinuations (n)
Time to 1st
discontinuation (months)
Time to 1st AE  discon-
tinuation (months)
Continuous adherence 
at 12/24 months(%) 
Etanercept 122 75 21.1 25.2 72.1/50.0%
Adalimumab 82 56 23.1 19.6 82.6/62.1%
Ustekinumab 33 16 25.9 28.4 83.3/60.0%
Infliximab 17 15 19.1 13.3 66.7/58.3%
Secukinumab 3 1 5.0 - -/-
Ixekizumab 1 - - - -/-
Efalizumab 3 3 7.3 - 0/0%
Golimumab 1 1 48.0 48.0 100/100%
Total 262 167
Table 3 - Causes of therapeutic discontinuation for each drug and the number and % of discontinuation per 
number of cycles.  
Causes of 
discontinuations
Etanercept
N=75
Adalimumab
n=56
Infliximab
n=15
Ustekinumab
n=16
Secukinumab
n=1
Efalizumab
n=3
Golimumab
n=1
Therapeutic 
failure
27 (22.1%) 21 (25.6%) 5 (29.4%) 4 (12.1%) 1 (33.3%) 2 (66.7%) -
AE 32 (26.2%) 12 (14.6%) 3 (17.6%) 5 (15.2%) - - 1 (100.0%)
Factors related 
to the patient
10 (8.2%) 12 (14.6%) 2 (11.8%) 4 (12.1%) - 1 (33.3%) -
Surgical inter-
vention
4 (3.3%) 5 (6.1%) 2 (11.8%) 1 (3.0%) - - -
Excellent clini-
cal response
3 (2.5%) 4 (4.9%) 2 (11.8%) 2 (6.1%) - - -
Pregnancy 2 (1.6%) - 1 (5.9%) - - - -
Other causes - 2 (2.4%) - - - - -
Total 78* 56 15 16 1 3 1
* in 3 cases there were 2 causes for drug discontinuation
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(56.6%), in 6 cases (11.3%) there was a switch to a different 
biologic agent and in the remaining 17 cases (32.1%) other 
therapeutic modalities were started.
Although differences were found between the four major 
biologic agents prescribed (etanercept, infliximab, ustekinu-
mab and adalimumab), they did not reach statistical signifi-
cance in the following aspects: number of discontinuations (t 
= 2.660, sig. 0.077) and percentage due to AE (t = 1.964, 
sig. 0.144), period until the first discontinuation due to AE (F 
0.329; sig. 0.804), differences in the number/percentage of 
discontinuations caused by each of the major AE (infections: 
t = 1.608, sig.0.206; neoplasms: t = 1.852, sig.0.161; he-
matological abnormalities: t = 2.333, sig. 0.102) and leng-
th of treatment until discontinuation (sig>0.05).
DISCUSSION
Therapeutic adhesion to biologic agents can be poor, 
with high rates of discontinuation and modification of treat-
ments.10,11 The main cause of discontinuation of biologic 
agents in the literature is primary or secondary therapeutic 
failure,2,7,12 a finding corroborated by our experience. 
Etanercept and infliximab showed the highest levels of 
discontinuation caused by AE, whereas ustekinumab showed 
the longest mean period of treatment until discontinuation 
due to AE, similar to previous studies.2,11-13 Infections and 
neoplasms were the commonest AE, causing discontinuation 
of 10.4% of the total number of therapeutic cycles. 
We found a higher percentage of therapeutic cycles dis-
continued due to AE (20.2%) than generally described in the 
literature,2,11,12 attributable to differences in methodology. 
We defined therapeutic discontinuation by a tight criterion, 
as the omission of 2 consecutive administrations of the drug, 
independent on the normal treatment intervals (1, 2, 4 or 12 
weeks), whether the patient was later initiated on another 
treatment or maintained on the previous, so that data could 
reflect, not only definitive suspensions followed by a switch 
of the drug, but also transient discontinuations soon resu-
ming the same biologic agent. 
Analyzing the context in which therapeutic disconti-
nuation occurred, two clearly different patterns emerged. 
Discontinuations due to primary or secondary therapeu-
tic failure were almost invariably advised by the physician 
(96.7%), and were followed by switching to another biologic 
in 93.3% of cases. Suspensions due to AE were more com-
monly on patient’s own initiative, without medical advice, 
were transient in the majority of cases (56.6% resumed the 
same biologic), and only 11.3% of the patients switched the 
biologic agent. AEs were a relatively rare cause of definiti-
ve therapeutic discontinuation and switch, probably because 
we also considered minor AE that led to temporary disconti-
nuation decided by the patient.
Our higher figures compared to other published re-
ports reflect this subgroup of temporary discontinuations 
caused by AE, not severe enough to justify a definitive dis-
continuation and therapeutic change, and frequently un-
derestimated. And there is evidence that even transient 
discontinuations may have consequences on the efficacy of 
the biologic agent, associating with worse long-term outco-
mes when compared with continuous treatment.14
Limitations of the study
Our study presents data obtained from a large sample 
in the real world practice. There are, however, several limi-
tations. All the 8 different drugs, that have different mecha-
nisms of action, different dosages and treatment protocols 
were evaluated in a global way, without considering the 
indication that motivated their use. Moreover, data were 
retrospectively collected, mostly from clinical records pro-
duced by different physicians, with the inherent subjectivity 
and biases in evaluations of efficacy, therapeutic failure as 
well as AE. Further data regarding the characterization of 
the population, including scores of disease severity, were 
not included due to an irregular use of standardized measu-
res or scores in the period in analysis. Differences between 
patients naive to biologic therapy and biologic-experienced 
patients were not studied. Moreover, we defined treatment 
discontinuation, the main objective of our study, as the in-
terruption of 2 successive doses, regardless of its cause and 
posterior therapeutic decisions, which may have a different 
impact for therapies programmed for intervals of 1 week 
or 12 weeks. 
CONCLUSION
We can conclude that therapeutic discontinuations during 
biologic therapy occurred under different scenarios, inclu-
ding non-medical oriented suspensions or often-neglected 
transient discontinuations. A mere analysis of switches of 
biologic agents would not give us the right perspective of 
therapeutic discontinuations, as many patients who tempo-
rarily discontinue treatment, even due to an AE, later resume 
the same biologic. 
Temporary discontinuations of biologic agents due to 
transient AE or other causes, often decided by the patient 
without medical indication, and not sufficiently valued by 
the dermatologist, are probably under-recognized and can 
contribute to a suboptimal pattern of use of these drugs and 
may have an impact on clinical outcomes.
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